Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is thought to exert its effects by enhancing the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).
### Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses may include other seizure types or anxiety disorders, but these are not FDA-approved indications.
### Adult Dosing
* **Lennox-Gastaut Syndrome:** Initial dose is typically 5 mg twice daily. Can be increased by 5-10 mg every week. Usual maintenance dose is 10-20 mg twice daily. Maximum dose is 40 mg daily. Titration should be slow to minimize adverse effects.
### Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 to <10 years):** Initial dose is typically 5 mg twice daily. Can be increased by 2.5-5 mg every week. Usual maintenance dose is 5-10 mg twice daily. Maximum dose is 10 mg twice daily (20 mg daily).
* **Lennox-Gastaut Syndrome (10 to <30 kg):** Initial dose is typically 5 mg twice daily. Can be increased by 5 mg every week. Usual maintenance dose is 10 mg twice daily. Maximum dose is 20 mg twice daily (40 mg daily).
* **Lennox-Gastaut Syndrome (≥30 kg):** Initial dose is typically 10 mg twice daily. Can be increased by 5-10 mg every week. Usual maintenance dose is 10-20 mg twice daily. Maximum dose is 20 mg twice daily (40 mg daily).
* **Note:** Dosing should be individualized based on clinical response and tolerability. A lower starting dose and slower titration may be warranted in certain pediatric populations.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses and slower titration are recommended due to potential for increased exposure.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established, but lower doses and slower titration may be considered.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
### Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, and gait disturbance. Serious adverse effects can include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, and withdrawal symptoms upon abrupt discontinuation.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedatives/hypnotics):** Additive CNS depressant effects, increasing the risk of sedation, respiratory depression, and profound coma.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is metabolized by CYP3A4. Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase clobazam levels. Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease clobazam levels.
* **Antiepileptic Drugs (AEDs):** Clobazam can affect levels of other AEDs (e.g., increasing levels of phenytoin, primidone; decreasing levels of valproic acid). Conversely, other AEDs can affect clobazam levels. Close monitoring of AED drug levels and clinical response is crucial.
### Monitoring
* **Clinical Efficacy:** Monitor for seizure frequency and severity.
* **Adverse Effects:** Assess for somnolence, behavioral changes, coordination issues, and signs of withdrawal.
* **Concomitant Medications:** Monitor for interactions, especially with other CNS depressants and AEDs.
* **Skin Reactions:** Counsel patients and caregivers to report any new or worsening rash immediately.
### Clinical Pearls
* Clobazam is often used as an adjunctive therapy for LGS and may help manage specific seizure types associated with this syndrome.
* Due to its long half-life, once-daily dosing is often possible for maintenance therapy.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Tapering of the dose is recommended upon discontinuation.
* Behavioral and psychiatric side effects, such as aggression and irritability, are notable and require careful monitoring, particularly in pediatric patients.
* Always counsel patients and caregivers on the risks of respiratory depression and CNS depression, especially when used with other sedating medications.
***
**Disclaimer:** This information is intended for clinical use and does not replace comprehensive drug monographs or current prescribing information. Always verify current dosing, indications, contraindications, and safety information with official product labeling and relevant clinical guidelines before prescribing or dispensing.
